Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma  by Boone, Brian A. et al.
ORIGINAL ARTICLE
Resection of isolated local and metastatic recurrence in
periampullary adenocarcinoma
Brian A. Boone1, Herbert J. Zeh1, Brady K. Mock2, Paul J. Johnson2, Igor Dvorchik1, Ken Lee1, A. James Moser3,
David L. Bartlett1 & J. Wallis Marsh1
1Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and 3Department
of Surgery, BIDMC, Boston, MA, USA
Abstract
Background: The majority of patients with periampullary cancer develop local or metastatic recurrence
despite successful negative margin resection. Unfortunately, there are no established therapeutic strat-
egies for managing these patients. The literature on the surgical resection of recurrent disease is limited.
Methods: This is a retrospective study evaluating patients who underwent reoperative resection of
recurrent periampullary cancer at a single institution between 1990 and 2011. Perioperative outcomes
were compared with those of the original primary resections for patients with local recurrence. Kaplan–
Meier curves were used to evaluate survival.
Results: Twenty-two patients underwent reoperative resection following the successful primary resec-
tion of periampullary cancers. Median survival from the time of reoperation was 28.1 months. A greater
survival benefit was seen in patients undergoing reoperative resection with >15 months between the
primary resection and recurrence (40.6 months versus 8.2 months; P < 0.05). Complication rates were
lower after reoperative resection compared with the primary resection (20% versus 70%). Perioperative
characteristics including operative time, estimated blood loss and hospital stay were similar in both the
primary and reoperation procedures.
Conclusions: Surgical resection of periampullary cancer recurrence is feasible, safe and may offer
survival benefits in comparison with alternative treatment modalities. Reoperative resection should be
considered, especially in patients in whom the time to recurrence is lengthy.
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Introduction
Despite being only the 10th most common cancer, periampullary
cancer is the fourth most common cause of cancer-related death
in the USA and just over 40 000 new cases are estimated to have
occurred in 2012.1 Surgical resection offers the only hope for
longterm survival, albeit that overall 5-year survival in resected
pancreatic cancer patients is poor and amounts roughly
10–20%.2–4 The poor survival in periampullary cancer patients
following resection reflects in part the substantial number of
patients who develop local recurrence despite surgical resection.
Up to 86% of patients have evidence of locoregional recurrence
following successful primary resection and an even larger number
develop hepatic disease.5,6 Distant metastases without evidence of
local recurrence or liver metastasis(es) are present in only 3% of
patients.5
Despite the high recurrence rates in periampullary cancer fol-
lowing primary resection, there are no established therapeutic
strategies for managing these patients.7,8 Improved survival has
been demonstrated following either surgery or chemotherapy;
therefore, treatment in some form may be warranted.9 Reopera-
tion for local recurrence is challenging and complex; however,
repeat pancreatic procedures have been demonstrated to be safe in
the hands of experienced surgeons.10 The surgical resection of
locally recurrent or isolated metastatic disease represents the best
hope for longterm survival. However, few patients are offered
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reoperation and only a small number of studies have evaluated the
efficacy of reoperative surgery in these patients. This report rep-
resents a single-institution experience of reoperation for locally
recurrent or isolated metastatic periampullary adenocarcinoma
following successful primary resection.
Materials and methods
Patient identification and data collection
The Institutional Review Board at the University of Pittsburgh
Medical Center (UPMC) approved this study prior to its initiation
(approval no. PRO11070165).
A retrospective search of the UPMC electronic health records
databases was performed to identify patients who had undergone
primary resection for periampullary cancer over the previous 12
years (1990–2011). Patients who underwent subsequent reopera-
tive resection with curative intent for locally recurrent or meta-
static disease were then identified. All pertinent medical records
were reviewed; these included operative reports, anaesthesia
records, daily progress notes, consultation notes, nursing notes,
and laboratory and radiology records and images. Perioperative
mortality and morbidity were evaluated over a 90-day postopera-
tive period. Complications were graded according to the Clavien–
Dindo system of classifying surgical complications.11
Patient follow-up after primary resection
There is no standardized postoperative surveillance protocol
for patients who undergo resection of primary periampullary
cancer at this institution. Most surgeons rely on carbohydrate
antigen 19-9 (CA 19-9) levels and routine standard computed
tomography (CT) to evaluate for recurrence, typically every 3
months during the first 2 years postoperatively and then yearly
until 5 years. Positron emission tomography (PET) CT scanning
is then utilized to confirm recurrent disease and monitor
response to treatment. All challenging cases are presented at a
multidisciplinary hepatopancreatobiliary conference at which
input from various specialty teams is obtained before the
surgeon makes any decision on how best to manage recurrent
disease.
Statistical analysis
IBM spss Version 20.0 (IBM Corp., Armonk, NY, USA) was used
for statistical analyses. Continuous data are presented as the mean,
median and/or range. Categorical variables are expressed as
numbers and percentages of the group from which they were
derived. Independent-sample t-tests were used to evaluate con-
tinuous data. Survival was estimated using the Kaplan–Meier
method. Survival was calculated from the time of resection.
Patients alive at the last follow-up were censored. Results were
considered statistically significant if they achieved P-values of
<0.05.
Results
Reoperations and indications
A total of 1707 patients who underwent primary resection for
periampullary cancer during the study period were identified
(1099 pancreaticoduodenectomies, 495 distal pancreatectomies,
113 total pancreatectomies). Of these, 22 patients (1.3%) subse-
quently underwent reoperative resection with curative intent for
local or metastatic periampullary cancer recurrence following
primary resection (Table 1). The median age of these patients was
67 years and 68% of them were female. Of the patients submitted to
resection, 10 (45%) underwent resection of local recurrence and 12
(55%) underwent resection of metastatic disease. Of the latter 12
patients, five (42%) were resected for lung metastases, one (8%) for
ovarian metastases and six (50%) for liver metastases.
Perioperative course
Perioperative outcomes in all patients submitted to resection of
local and metastatic recurrence are reported in Table 2. In Table 3,
perioperative outcomes following primary resection are com-
pared with outcomes of reoperation in patients with locally recur-
rent disease. Reoperation was associated with a lower median
operative time than primary resection (364 min versus 616 min;
P < 0.05). Patients were discharged sooner (12 days versus 9 days;
P < 0.05) and were more likely to be discharged to home (100%
versus 90%) following reoperation than after primary resection.
Morbidity and mortality
There was no perioperative mortality. Perioperative complications
affected 32% of patients. All complications were classed as
Grade III.
Survival
Reoperative resection with curative intent resulted in median post-
operative survival of 28.1 months; six patients (27%) remained
alive at the last follow-up. Three patients (14%) survived for >5
years. Median survival in these patients from the date of primary
resection was 60.6 months. Survival in patients undergoing cura-
tive resection was greater in those who experienced >15 months of
recurrence-free survival after the primary resection (40.6 months
versus 8.2 months; P < 0.05) (Fig. 1a). There was no significant
difference in median survival between patients with ampullary
versus patients with pancreatic cancers (30.8 months versus 20.2
months; P = 0.9) (Fig. 1b). Median survival in patients with local
recurrence was 31.8 months, whereas median survival in patients
with lung recurrence was 27.6 months and patients with liver
recurrence was 13.9 months; however, there was no statistical
difference in outcomes according to whether resection was carried
out for local or metastatic disease (P= 0.14) (Fig. 1c). Additionally,
there was no statistically significant benefit to resection of isolated
lung metastases compared to local recurrence or liver metastases.
Univariate analyses were performed to identify which patients
would benefit most from reoperative resection; however, no vari-
ables generated differences of statistical significance.
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Discussion
Despite the unfortunate frequency with which surgeons are
confronted with recurring periampullary cancer following
curative resection, there are few reports of the surgical resection
of recurrent disease. The present data represent a series of 22
patients submitted to reoperative resection for locally recurrent
or isolated metastatic periampullary adenocarcinoma. These
results suggest that the resection of recurrent cancer may
provide a possible survival benefit without incurring significant
morbidity.
Surgical resection of locally recurrent or isolated metastatic
disease represents the best hope for longterm survival; however,
few patients are offered reoperation. The potential resection of
local or metastatic recurrence is an uncommon treatment sce-
nario. This series of 22 patients undergoing reoperative resection
represents 1.3% of all patients submitted to primary resection of
periampullary cancer during the study period at this centre. This
is likely to reflect the fact that few patients present with isolated,
stable local or metastatic disease that is suitable for resection.
Additionally, this uncommon group of patients is unlikely to be
offered resection, largely because data evaluating surgery as a
treatment modality for recurrent disease are lacking. A number of
single case reports of completion pancreatectomy for disease in
the remnant pancreas are available and many of these report sig-
nificant longterm survival (up to 48 months without considerable
morbidity).12–22 Only three case series have evaluated reoperation
for recurrent periampullary adenocarcinoma. Most recently,
Thomas et al. reported a series of 21 patients undergoing reopera-
tive resection of local or metastatic recurrence of pancreatic ductal
adenocarcinoma following primary resection.23 The authors dem-
onstrated a survival benefit in patients who had experienced >20
months of disease-free survival prior to recurrence; however, the
greatest benefit was seen in patients with isolated pulmonary
metastases. The authors concluded that patients with isolated pul-
monary metastases with a long disease-free interval should be
considered for reoperation.23 Zacharias et al. published the results
of 15 re-laparotomies for recurrent periampullary malignancies
and found slightly improved survival in patients who presented
for elective resection.24 A study by Kleef et al. evaluated 30 patients
with recurrent pancreatic cancer, of whom 15 underwent either
palliative bypass or abdominal exploration alone and 15 under-
went resection of local recurrence or metastatic disease.25
Although the resection group showed a tendency towards
improved survival, the difference did not reach statistical
significance.25
Although a small number of patients present with isolated,
stable metastatic periampullary cancer (most commonly to the
lungs and liver), the literature on the optimal management of such
disease is lacking. A small number of single case reports have
described the resection of stable liver metastases and reported
survival of up to 29 months.18,19,26,27 Arnaouakis et al. reported a
series of nine patients submitted to pulmonary metastasectomy
with curative intent for pancreatic cancer and demonstrated an
impressive longterm survival of 51 months with no morbidity or
perioperative mortality.28
These data demonstrate that reoperative resection of periamp-
ullary cancer recurrence is feasible and safe. No operative compli-
cations or perioperative mortality occurred in the present series of
22 patients. Compared with the primary resection, reoperation for
local recurrence was associated with a shorter operative time and
length of stay. Despite the greater technical demands associated
with reoperation, there was no difference between reoperation
and primary resection procedures with a similar operative risk in
estimated blood loss, transfusion rate or morbidity. This lower
morbidity in part reflects the lack of risk for pancreatic fistula
following reoperation, which contributes significantly to morbid-
ity following to primary resection.
This series revealed a median survival following reoperative
resection of 28.1 months and six patients remained alive at the
last follow-up timepoint. As previous authors reporting on reop-
erative resection have concluded,25 survival was dramatically
improved in patients who underwent resection of recurrent
disease at >15 months after primary resection. There are two
hypotheses that may explain why a longer latency period results in
improved survival. The two-hit hypothesis centres on the idea that
‘recurrent’ cancer actually represents a second primary cancer,
which would support the resection of ‘recurrent’ tumours. An
alternative explanation is that, as a result of their biology, slow-
growing tumours that have a longer latency between presentations
portend a better overall prognosis, which again supports the con-
sideration of surgical resection in these patients. The present
analysis found a trend towards higher survival in local recurrence
(31.8 months) and lung metastases (27.6 months) compared with
liver metastases (13.9 months); however, this trend did not reach
statistical significance. It is possible that a larger study population
Table 2 Perioperative outcomes in patients undergoing reoperative
resection of recurrent periampullary cancer (n = 22)
Operative time, min, median (range) 232 (77–435)
Blood loss, ml, median (range) 300 (25–6000)
Required PRBC Transfusion, n (%) 6 (27%)
Length of stay, days, mean (median; range) 8 (7; 2–28)
Disposition, n (%)
Home 22 (100%)
SNF/rehabilitation 0
Morbidity, n (%)
All grades 7 (32%)
Grade 1 2 (29%)
Grade II 2 (29%)
Grade III 3 (42%)
Grade IV 0
Perioperative mortality, n (%) 0
PRBC, packed red blood cells; SNF, skilled nursing facility.
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Table 3 Perioperative outcomes in patients undergoing reoperative resection for periampullary cancer local recurrence at the primary
resection and at reoperation (n = 22)
At primary resection At reoperation P-value
Operative time, min, median (range) 616 (223–771) 364 (109–558) <0.05
Blood loss, ml, median (range) 450 (75–700) 300 (50–6000) 0.38
Required PRBC Transfusion, n (%) 3 (30%) 2 (20%)
Length of stay, days, mean (median; range) 12 (12; 6–25) 9 (10; 3–15) <0.05
Disposition, n (%)
Home 9 (90%) 10 (100%)
SNF/rehabilitation 1 (10%) 0
Morbidity, n (%)
All grades 7 (70%) 2 (20%)
Grade I 2 (29%) 0
Grade II 3 (43%) 1 (50%)
Grade III 2 (29%) 1 (50%)
Grade IV 0 0
Perioperative mortality, n (%) 0 0
PRBC, packed red blood cells; SNF, skilled nursing facility.
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Figure 1 Kaplan–Meier curves showing survival following reoperative resection of periampullary cancer recurrence by (a) time to recurrence,
(b) type of cancer and (c) site of recurrent disease
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might indicate a survival advantage associated with resection
of local recurrence or lung metastases compared with liver
metastases.
Periampullary cancers are notoriously insensitive to chemo-
therapy, especially in the setting of recurrence; response rates are
reported to be 10–30%.29,30 As a result, chemotherapy is combined
with radiation to improve response rates and is the most com-
monly utilized treatment for local recurrence. Wilkowski et al.
described a series of 18 patients with isolated local recurrence who
underwent radiation plus combination chemotherapy of
5-fluorouracil (5-FU) with gemcitabine and/or cisplatin.31
Median overall survival from the start of chemoradiotherapy was
17.5 months and only 37% of patients achieved complete remis-
sion. These data put the 28.1-month postoperative survival dem-
onstrated in the present study into perspective. Because this is a
retrospective study with significant selection bias, it does not
support conclusions on survival outcomes in patients treated with
surgery compared with those treated with chemoradiation. More
recently, FOLFIRINOX [folinic acid (leucovorin calcium), fluor-
ouracil (5-FU), irinotecan hydrochloride, oxaliplatin] has shown
promising results in treating pancreatic cancer.32 However, data on
the treatment of recurrent disease are limited and further study is
warranted.33,34 To date, studies evaluating FOLFIRINOX have
assessed the regimen in the metastatic setting, demonstrating sur-
vival of 8–11 months.32,35,36
The present data should be interpreted with caution as this
study has several limitations. This is a retrospective series and
definitive conclusions cannot be made without a prospective, ran-
domized controlled trial, which is, admittedly, a difficult proposal
that is unlikely to be enacted. This series of patients is clearly a
heterogeneous population in that it includes patients with local
recurrence as well as those with metastatic disease, and patients
with both ampullary and pancreatic adenocarcinoma, and thus
the data are more difficult to extrapolate. Unfortunately, this
population heterogeneity is necessary because the number of
patients undergoing reoperation for pancreatic cancer recurrence
is limited. This series represents a limited number of patients over
a 12-year period, which suggests that only a select number of
patients have isolated recurrent disease and are thus suitable for
surgical resection. In addition, the study is limited by its method-
ology, which allowed for the identification of patients who under-
went a primary resection at this institution only; it is likely that the
present data exclude a small number of patients who underwent
primary resection at an outside institution and resection of recur-
rent disease at the study institution. Unfortunately, there is no way
of identifying these patients by searching operative records.
Despite these limitations, these data suggest that the resection of
recurrent periampullary cancer is feasible, can be safely accom-
plished in a wide variety of patients, and preliminarily appears to
offer a significant survival advantage over alternative treatments.
Not all patients are suitable for surgical re-resection and therefore
further research is warranted to identify factors that predict which
patients may benefit most from the resection of recurrent disease.
Conclusions
Surgical resection of periampullary cancer recurrence should at
least be considered by specialized, experienced oncology surgeons,
especially in patients in whom the time to recurrence is relatively
long. Despite its significant technical challenges, reoperative resec-
tion is feasible and safe, and offers the best hope for longterm
survival in patients with isolated metastatic or locally recurrent
periampullary cancer.
Acknowledgements*
This work was supported by the National Institutes of Health under
the Ruth L. Kirschstein National Research Service Award, grant number
T32CA113263.
Conflicts of interest
None declared.
References
1. Siegel R, Naishadham D, Jemal A. (2012) Cancer statistics. CA Cancer J
Clin 62:10–29.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. (2006) One thousand
consecutive pancreaticoduodenectomies. Ann Surg 244:10–15.
3. Conlon KC, Klimstra DS, Brennan MF. (1996) Longterm survival after
curative resection for pancreatic ductal adenocarcinoma. Clinicopatho-
logic analysis of 5-year survivors. Ann Surg 223:273–279.
4. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. (1995) Longterm survival
after resection for ductal adenocarcinoma of the pancreas. Is it really
improving? Ann Surg 221:59–66.
5. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. (1997) Recurrence after
resection for ductal adenocarcinoma of the pancreas. World J Surg
21:195–200.
6. Westerdahl J, Andren-Sandberg A, Ihse I. (1993) Recurrence of exocrine
pancreatic cancer – local or hepatic? Hepatogastroenterology 40:384–
387.
7. Kyriazanos ID, Tsoukalos GG, Papageorgiou G, Verigos KE, Miliadis L,
Stoidis CN. (2011) Local recurrence of pancreatic cancer after primary
surgical intervention: how to deal with this devastating scenario? Surg
Oncol 20:e133–e142.
8. Sunamura M, Egawa S, Shibuya K, Shimamura H, Takeda K, Kobari M
et al. (1999) [Therapeutic strategy for the recurrence of pancreatic cancer
following pancreatectomy.] Nihon Geka Gakkai Zasshi 100:200–205.
9. Menke-Pluymers MB, Klinkenbijl JH, Tjioe M, Jeekel J. (1992) Treatment
of locoregional recurrence after intentional curative resection of pancre-
atic cancer. Hepatogastroenterology 39:429–432.
10. Kersting S, Janot MS, Chromik AM, Suelberg D, Uhl W, Seelig MH. (2011)
Contemporary single-centre surgical experiences in redo procedures of
the pancreas: improved outcome and reduction of operative risk. J Gas-
trointest Surg 15:191–198.
11. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD
et al. (2009) The Clavien–Dindo classification of surgical complications:
five-year experience. Ann Surg 250:187–196.
* This information was added on 7 August 2013, after first online
publication.
202 HPB
HPB 2014, 16, 197–203 © 2013 International Hepato-Pancreato-Biliary Association
12. Eriguchi N, Aoyagi S, Imayama H, Okuda K, Hara M, Fukuda S et al.
(2000) Resectable carcinoma of the pancreatic head developing 7 years
and 4 months after distal pancreatectomy for carcinoma of the pancreatic
tail. J Hepatobiliary Pancreat Surg 7:316–320.
13. Niiyama H, Yamaguchi K, Shimizu S, Yokohata K, Chijiiwa K, Yonemasu
H et al. (1998) Pancreatic carcinoma in remnant pancreas after pancrea-
tectomy for mucinous cystadenoma. Eur J Gastroenterol Hepatol
10:703–707.
14. Wada K, Takada T, Yasuda H, Amano H, Yoshida M. (2001) A repeated
pancreatectomy in the remnant pancreas 22 months after pylorus-
preserving pancreatoduodenectomy for pancreatic adenocarcinoma.
J Hepatobiliary Pancreat Surg 8:174–178.
15. Dalla Valle R, Mancini C, Crafa P, Passalacqua R. (2006) Pancreatic
carcinoma recurrence in the remnant pancreas after a pancreaticoduo-
denectomy. JOP 7:473–477.
16. D'Amato A, Gentili V, Santella S, Boschetto A, Pronio A, Montesani C.
(2002) [Carcinoma of the pancreatic remnant developing after pancrea-
ticoduodenectomy for adenocarcinoma of the head of pancreas.] Chir Ital
54:539–544.
17. Takamatsu S, Ban D, Irie T, Noguchi N, Kudoh A, Nakamura N et al.
(2005) Resection of a cancer developing in the remnant pancreas after a
pancreaticoduodenectomy for pancreas head cancer. J Gastrointest
Surg 9:263–269.
18. Hayashi N, Soma I, Nakano K, Higaki N, Murakami M, Hayashida H et al.
(2009) [Repeated resections of asynchronous liver metastases after pan-
creatomy for pancreatic cancer – a case report.] Gan To Kagaku Ryoho
36:2410–2412.
19. Seelig MH, Janot M, Chromik AM, Herzog T, Belyaev O, Weyhe D et al.
(2009) Redo-surgery following curative resection of pancreatic carci-
noma: the difference between true and suspected recurrence. Dig Surg
26:222–228.
20. Kim C, Tono T, Kimura Y, Watanabe A, Nakamura H, Inadome J et al.
(2011) [Re-resection for local recurrence in the remnant pancreas after
pancreaticoduodenectomy for pancreatic cancer – a case report.] Gan To
Kagaku Ryoho. 38:2448–2450.
21. Kinoshita H, Yamade N, Nakai H, Sasaya T, Matsumura S, Kimura A et al.
(2011) Successful resection of pancreatic carcinoma recurrence in the
remnant pancreas after a pancreaticoduodenectomy. Hepatogastroen-
terology 58:1406–1408.
22. Ogino T, Ueda J, Sato N, Takahata S, Mizumoto K, Nakamura M et al.
(2010) Repeated pancreatectomy for recurrent pancreatic carcinoma
after pylorus-preserving pancreatoduodenectomy: report of two patients.
Case Rep Gastroenterol 4:429–434.
23. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN,
Pisters PW et al. (2012) Selective reoperation for locally recurrent or
metastatic pancreatic ductal adenocarcinoma following primary pancre-
atic resection. J Gastrointest Surg 16:1696–1704.
24. Zacharias T, Oussoultzoglou E, Jaeck D, Pessaux P, Bachellier P. (2009)
Surgery for recurrence of periampullary malignancies. J Gastrointest Surg
13:760–767.
25. Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D et al. (2007)
Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg
245:566–572.
26. Kobayashi S, Ohashi M, Tenma N, Matsuura H. (2007) [A case with a
single liver metastasis from pancreatic cancer surviving for 29 months.]
Gan To Kagaku Ryoho 34:1671–1674.
27. Ota K, Yamamoto T, Matsumura T, Fukunaga M, Ohzato H, Miwa H et al.
(2009) [A case of surgical treatment of solitary liver metastasis from
pancreatic cancer.] Gan To Kagaku Ryoho 36:2407–2409.
28. Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA,
Hruban RH, Herman JM et al. (2011) Pulmonary resection for isolated
pancreatic adenocarcinoma metastasis: an analysis of outcomes and
survival. J Gastrointest Surg 15:1611–1617.
29. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore
DF Jr et al. (2004) Gemcitabine and ISIS-2503 for patients with
locally advanced or metastatic pancreatic adenocarcinoma: a North
Central Cancer Treatment Group Phase II trial. J Clin Oncol 22:4944–
4950.
30. Heinemann V, Labianca R, Hinke A, Louvet C. (2007) Increased survival
using platinum analogue combined with gemcitabine as compared to
single-agent gemcitabine in advanced pancreatic cancer: pooled analy-
sis of two randomized trials, the GERCOR/GISCAD intergroup study and
a German multicentre study. Ann Oncol 18:1652–1659.
31. Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. (2006) Com-
bined chemoradiotherapy for isolated local recurrence after primary
resection of pancreatic cancer. JOP 7:34–40.
32. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y
et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic
cancer. N Engl J Med 364:1817–1825.
33. dos Santos LV, de Andrade DP, Lima JP. (2012) FOLFIRINOX: a great
leap forward, but for whom? J Clin Oncol 30:114–115. [Authors' reply.]
34. Kim R. (2011) FOLFIRINOX: a new standard treatment for advanced
pancreatic cancer? Lancet Oncol 12:8–9.
35. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel
D et al. (2011) 5-fluorouracil/leucovorin combined with irinotecan and
oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with
metastatic pancreatic adenocarcinoma. Oncology 80:301–306.
36. Conroy T, Mitry E. (2011) [Chemotherapy of metastatic pancreatic adeno-
carcinoma: challenges and encouraging results.] Bull Cancer 98:1439–
1446.
HPB 203
HPB 2014, 16, 197–203 © 2013 International Hepato-Pancreato-Biliary Association
